A Look at Intercept Pharmaceuticals’ Cash Flows
Intercept Pharmaceuticals (ICPT) spent $265.4 million on operating activities in fiscal 2017 compared with $342.4 million in fiscal 2016. In fiscal 2017, Intercept Pharmaceuticals generated $2.8 million from financing activities, which were mainly from the exercise of options to purchase common stock. On April 5, 2018, Intercept Pharmaceuticals announced pricing of the upsized $250 million public offering of its common stock with a concurrent private placement of 1.5 million of its common shares.